Equillium, Inc. EQ
Equillium, Inc. (Nasdaq: EQ) is a GI/hepatology drug developer. Its lead program, EQ504, is in Pre-clinical for ulcerative colitis and other GI diseases (inflammatory lung diseases as expansion). Its next catalyst on record is EQ504: Initiate Phase 1 placebo-controlled proof-of-mechanism study (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EQ504 — Initiate Phase 1 placebo-controlled proof-of-mechanism study (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EQ504 (aryl hydrocarbon receptor modulator) | ulcerative colitis / GI diseases | small molecule | Pre-clinical |
| EQ302 (bispecific IL-15/IL-21 inhibitor, oral) | celiac disease / inflammatory bowel disease | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.